Key result
Tangeretin downregulated ANGPTL3 expression and augmented LPL activity in hepatic cells by counteracting LXRα-mediated transcription, suggesting a potential lipid-lowering effect.
Why the study?
Excessive accumulation of TG-rich lipoproteins in plasma is associated with dyslipidemia and ASCVD, and the lipid-modulating effects and underlying mechanisms of tangeretin in hepatic cells required investigation.
Does tangeretin reduce ANGPTL3 gene expression and augment LPL activity in hepatic cells?
Population
Hepatic cells (HepG2 and Huh-7 cells)
Comparison
Tangeretin treatment vs untreated cells
Design
In vitro preclinical laboratory study
Authors
Loading...
Tangeretin may lower lipids via hepatic LXRα-ANGPTL3-LPL; hypothesis-generating in animals and should not change practice.
Does tangeretin reduce ANGPTL3 gene expression and augment LPL activity in hepatic cells?
Tangeretin exerts a lipid-lowering effect by modulating the LXRα-ANGPTL3-LPL pathway in hepatic cells, suggesting its potential as a phytochemical for dyslipidemia prevention or treatment.
Chen et al. (2021) studied Dyslipidemia. Tangeretin was evaluated on ANGPTL3 gene expression and LPL activity. Tangeretin downregulated ANGPTL3 expression and augmented LPL activity in hepatic cells by counteracting LXRα-mediated transcription, suggesting a potential lipid-lowering effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: